Medtronic Plc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
7.9%projected annual EPS growth
Analyst Coverage
25analysts covering
FY Revenue (est.)
$38.8Bnext fiscal year
FY EPS (est.)
$5.95next fiscal year
Monitoring Framework
Key Performance Indicators
Scope 1 and 2 Emissions Intensity Reduction (vs FY20 baseline) Annually0.6Target: 50% reduction by FY25 (exceeded), net carbon neutrality in operations by FY30
Energy Intensity Reduction (vs FY20 baseline) Annually0.2Target: 35% reduction by FY30
Waste Intensity Reduction (vs FY20 baseline) Annually0.2Target: 40% reduction by FY30
Water Use Reduction (vs FY20 baseline) Annually0.2Target: 30% reduction by FY30
Patients Served Annually82MTarget: 82 million in FY26
Watch Items
- Diabetes Segment Separation (MiniMed)Trigger: Completion of full divestiture (currently ~90% owned by Medtronic post-IPO)Action: Monitor tax implications, capital allocation, and margin expansion post-separation expected near end of calendar year 2026.
- Medical Surgical Portfolio Goodwill CushionTrigger: Fair value cushion drops below 12% of carrying valueAction: Assess potential asset impairment write-downs if segment performance or margins deteriorate.
- Surgical Robotics (Hugo System) AdoptionTrigger: Market share gains vs. entrenched competitors like Intuitive SurgicalAction: Track clinical trial progress, regulatory approvals, and hospital system capital expenditure trends.
Research as of 2 Sep 2026